Subtopic Deep Dive
KIT Mutations Gastrointestinal Stromal Tumors
Research Guide
What is KIT Mutations Gastrointestinal Stromal Tumors?
KIT mutations in gastrointestinal stromal tumors (GISTs) are activating oncogenic alterations in the KIT tyrosine kinase gene that drive tumor oncogenesis and determine imatinib sensitivity.
Over 80% of GISTs harbor KIT mutations, primarily in exons 11 and 9, correlating with distinct clinical phenotypes and drug responses (Heinrich et al., 2003, 2278 citations). Exon 11 mutations predict higher imatinib response rates than exon 9 mutations. Approximately 120 papers characterize these mutation-specific effects as of 2024.
Why It Matters
KIT mutation profiling guides precision therapy in GIST patients, with exon 11 mutants showing 83% response to imatinib versus 48% for exon 9 (Heinrich et al., 2003). Demetri et al. (2002, 4350 citations) demonstrated sustained responses in 54% of advanced GIST patients treated with imatinib targeting KIT signaling. Secondary KIT mutations cause acquired resistance, informing second-line therapies like sunitinib (Antonescu et al., 2005). This enables personalized treatment selection, improving progression-free survival in metastatic disease.
Key Research Challenges
Secondary KIT Resistance Mutations
Acquired mutations in KIT kinase domain during imatinib therapy restore oncogenic signaling (Antonescu et al., 2005, 822 citations). Common sites include ATP-binding pocket and activation loop. Developing multi-kinase inhibitors addressing polyclonal resistance remains difficult.
Exon 9 Mutation Detection
Exon 9 KIT mutations occur in 10-15% of GISTs and require higher imatinib doses, but routine genotyping often misses them (Heinrich et al., 2003). Low mutation allele frequency complicates PCR-based detection. Accurate subtyping demands next-generation sequencing.
Predicting Mutant KIT Sensitivity
In vitro sensitivity varies by KIT exon mutation despite structural similarities (Corless et al., 2005). Clinical trials show dose-response differences unresolved by genotype alone (Blanke et al., 2008, 997 citations). Functional assays for novel inhibitors are needed.
Essential Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · 2002 · New England Journal of Medicine · 4.3K citations
Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction p...
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al. · 2003 · Journal of Clinical Oncology · 2.3K citations
Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential the...
Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
Markku Miettinen, Jerzy Lasota · 2001 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 1.8K citations
Somatic Activation of KIT in Distinct Subtypes of Melanoma
John A. Curtin, Klaus J. Busam, Daniel Pinkel et al. · 2006 · Journal of Clinical Oncology · 1.6K citations
Purpose Melanomas on mucosal membranes, acral skin (soles, palms, and nail bed), and skin with chronic sun-induced damage have infrequent mutations in BRAF and NRAS, genes within the mitogen-activa...
Gastrointestinal Stromal Tumors: Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis
Markku Miettinen, Jerzy Lasota · 2006 · Archives of Pathology & Laboratory Medicine · 1.4K citations
Abstract Context.—Gastrointestinal stromal tumors (GISTs) are specific, generally Kit (CD117)-positive, mesenchymal tumors of the gastrointestinal tract encompassing a majority of tumors previously...
Gastrointestinal Stromal Tumors of the Stomach
Markku Miettinen, Leslie H. Sobin, Jerzy Lasota · 2004 · The American Journal of Surgical Pathology · 1.2K citations
Gastrointestinal (GI) stromal tumors (GISTs), the specific KIT- or PDFGRA-signaling driven mesenchymal tumors, are the most common mesenchymal tumors of the GI tract. In this study, we analyzed 186...
Biology of Gastrointestinal Stromal Tumors
Christopher L. Corless, Jonathan A. Fletcher, Michael C. Heinrich · 2004 · Journal of Clinical Oncology · 1.2K citations
Once a poorly defined pathologic oddity, in recent years, gastrointestinal stromal tumor (GIST) has emerged as a distinct oncogenetic entity that is now center stage in clinical trials of kinase-ta...
Reading Guide
Foundational Papers
Read Demetri et al. (2002, 4350 citations) first for imatinib efficacy proof; Heinrich et al. (2003, 2278 citations) next for mutation-response correlations; Miettinen & Lasota (2001, 1839 citations) for GIST definition and KIT role.
Recent Advances
Study Blanke et al. (2008, 997 citations) for long-term high-dose imatinib results; Antonescu et al. (2005, 822 citations) for resistance mechanisms; Corless et al. (2005, 831 citations) for PDGFRA comparison.
Core Methods
PCR sequencing for mutation detection (Heinrich et al., 2003); immunohistochemistry for KIT (CD117) expression (Miettinen & Lasota, 2006); in vitro kinase assays for inhibitor sensitivity (Corless et al., 2005).
How PapersFlow Helps You Research KIT Mutations Gastrointestinal Stromal Tumors
Discover & Search
Research Agent uses searchPapers('KIT exon 11 mutations GIST imatinib response') to retrieve Heinrich et al. (2003), then citationGraph to map 2278 citing papers on resistance mechanisms, and findSimilarPapers to uncover exon 9-specific studies.
Analyze & Verify
Analysis Agent applies readPaperContent on Heinrich et al. (2003) to extract mutation-response data, runPythonAnalysis to plot response rates by exon (NumPy/pandas), and verifyResponse with CoVe to GRADE evidence as high-quality (Level 1b from RCT data). Statistical verification confirms 83% vs 48% response rates (p<0.001).
Synthesize & Write
Synthesis Agent detects gaps in secondary mutation therapies via contradiction flagging across Antonescu et al. (2005) and Blanke et al. (2008), then Writing Agent uses latexEditText for mutation tables, latexSyncCitations for 10-paper bibliography, and latexCompile for review manuscript.
Use Cases
"Analyze survival data from imatinib trials by KIT mutation type"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Demetri 2002 + Heinrich 2003 data) → matplotlib plot of PFS by exon 11 vs 9.
"Draft review section on KIT mutations in GIST with figures"
Synthesis Agent → gap detection → Writing Agent → latexEditText (text) → latexGenerateFigure (mutation spectrum) → latexSyncCitations (Heinrich 2003) → latexCompile → PDF output.
"Find analysis code for KIT mutation frequency in GIST cohorts"
Research Agent → paperExtractUrls (Corless 2004) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (replicate mutation tally from Miettinen datasets).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ KIT/GIST papers: searchPapers → citationGraph → DeepScan 7-step verification → structured report with GRADE scores. Theorizer generates hypotheses on exon 9 resistance from Heinrich (2003) + Antonescu (2005) signaling data. DeepScan analyzes Demetri (2002) trial with CoVe checkpoints for mutation-stratified efficacy.
Frequently Asked Questions
What defines KIT mutations in GIST?
KIT mutations are gain-of-function alterations in exons 9, 11, 13, or 17 that constitutively activate tyrosine kinase signaling, present in 80-90% of GISTs (Miettinen & Lasota, 2001; Heinrich et al., 2003).
How do KIT mutations predict imatinib response?
Exon 11 mutations yield 83% partial response or stable disease; exon 9 mutations respond in 48% at standard dose, improved to 67% with high dose (Heinrich et al., 2003; Blanke et al., 2008).
What are key papers on KIT mutations in GIST?
Heinrich et al. (2003, 2278 citations) established genotype-response correlations; Demetri et al. (2002, 4350 citations) showed 54% response rate; Antonescu et al. (2005) identified secondary resistance mutations.
What open problems exist in KIT mutation research?
Overcoming polyclonal secondary mutations, developing exon 9-specific inhibitors, and integrating liquid biopsy for real-time genotyping remain unsolved (Antonescu et al., 2005; Corless et al., 2005).
Research Gastrointestinal Tumor Research and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching KIT Mutations Gastrointestinal Stromal Tumors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers